Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tate M Johnson

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Annals of the Rheumatic Diseases|May 29, 2021
Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritisTate M Johnson, Harlan R Sayles, Joshua F Baker, et al.
Frontiers in Immunology|December 10, 2025
Malondialdehyde-acetaldehyde modified macromolecules and resulting autoantibodies in rheumatoid arthritis pathogenesis: a Systematic Literature ReviewWenxian Zhou, Nozima Aripova, Hannah J Johnson, et al.
JAMA Internal Medicine|July 31, 2023
Aortic Stenosis Risk in Rheumatoid ArthritisTate M Johnson, Chetaj A Mahabir, Yangyuna Yang, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 29, 2024
The Risk of Lung Cancer in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung DiseaseRebecca T Brooks, Brent Luedders, Austin Wheeler, et al.
Arthritis Care & Research|March 21, 2022
Circulating Adipokines and Associations With Incident Cardiovascular Disease in Rheumatoid ArthritisLydia E Federico, Tate M Johnson, Bryant R England, et al.
The Lancet. Rheumatology|January 10, 2025
Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort studyBryant R England, Joshua F Baker, Michael D George, et al.
Seminars in Arthritis and Rheumatism|April 25, 2025
Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: A propensity score-matched, active-comparator, new-user studyHalie Frideres, Christopher S Wichman, Jianghu Dong, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 9, 2026
Performance of the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Calculator in Rheumatoid ArthritisTate M Johnson, Halie Frideres, Punyasha Roul, et al.
Rheumatology (Oxford, England)|October 9, 2023
Serum alarmins and the risk of incident interstitial lung disease in rheumatoid arthritisJill A Poole, Bryant R England, Harlan Sayles, et al.
Current Issues in Molecular Biology|November 26, 2025
Citrullinated and Malondialdehyde-Acetaldehyde-Modified Fibrinogen Activates Macrophages and Promotes Coronary Endothelial Cell InflammationWenxian Zhou, Hannah J Johnson, Michael J Duryee, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Annals of the Rheumatic Diseases|May 29, 2021
Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritisTate M Johnson, Harlan R Sayles, Joshua F Baker, et al.
Frontiers in Immunology|December 10, 2025
Malondialdehyde-acetaldehyde modified macromolecules and resulting autoantibodies in rheumatoid arthritis pathogenesis: a Systematic Literature ReviewWenxian Zhou, Nozima Aripova, Hannah J Johnson, et al.
JAMA Internal Medicine|July 31, 2023
Aortic Stenosis Risk in Rheumatoid ArthritisTate M Johnson, Chetaj A Mahabir, Yangyuna Yang, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 29, 2024
The Risk of Lung Cancer in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung DiseaseRebecca T Brooks, Brent Luedders, Austin Wheeler, et al.
Arthritis Care & Research|March 21, 2022
Circulating Adipokines and Associations With Incident Cardiovascular Disease in Rheumatoid ArthritisLydia E Federico, Tate M Johnson, Bryant R England, et al.
The Lancet. Rheumatology|January 10, 2025
Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort studyBryant R England, Joshua F Baker, Michael D George, et al.
Seminars in Arthritis and Rheumatism|April 25, 2025
Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: A propensity score-matched, active-comparator, new-user studyHalie Frideres, Christopher S Wichman, Jianghu Dong, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 9, 2026
Performance of the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Calculator in Rheumatoid ArthritisTate M Johnson, Halie Frideres, Punyasha Roul, et al.
Rheumatology (Oxford, England)|October 9, 2023
Serum alarmins and the risk of incident interstitial lung disease in rheumatoid arthritisJill A Poole, Bryant R England, Harlan Sayles, et al.
Current Issues in Molecular Biology|November 26, 2025
Citrullinated and Malondialdehyde-Acetaldehyde-Modified Fibrinogen Activates Macrophages and Promotes Coronary Endothelial Cell InflammationWenxian Zhou, Hannah J Johnson, Michael J Duryee, et al.
Pageof 3